Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.

Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
Infez Med. 2018 Dec 01;26(4):336-340
Authors: Ciccullo A, D'Avino A, Lassandro AP, Baldin G, Borghetti A, Dusina A, Emiliozzi A, Gagliardini R, Moschese D, Belmonti S, Lombardi F, Di Giambenedetto S
Abstract
Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.
PMID: 30555137 [PubMed - in process]

Source: Infezioni in Medicina - December 19, 2018 Category: Infectious Diseases Tags: Infez Med Source Type: research